The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to the ‘Road to Brexit’ speech by Prime Minister Theresa May
In a speech given 2 March, the Prime Minister stated:
Reacting to the speech, Chief Executive of the ABPI, Mike Thompson said:
The pharmaceutical industry’s policy priorities for Brexit are: